Prevalence of the Metabolic Syndrome in Kidney Transplantation

Kishikawa, Hiroki; Nishimura, Kenji; Kato, Taigo; Kobayashi, Yasuyuki; Arichi, Naoko; Okuno, Ayako; Fujii, Naohiko; M, Kyo; Takahara, Shiro; Ichikawa, Yasuji

doi:10.1016/j.transproceed.2008.10.091

Cited by 10 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In kidney transplant patient populations, the reported prevalence of metabolic syndrome varies widely from as low as 14.9% to as high as 65%, likely reflecting the difference in populations studied (2, 18–20). The presence of MS is associated with the risk of developing NODAT.…”

Section: Discussionmentioning

confidence: 99%

“…Metabolic syndrome is present in over 20% of US adults over the age of twenty and predicts the future risk for adverse cardiovascular outcomes (15)(16)(17). In kidney transplant patient populations, the reported prevalence of metabolic syndrome varies widely from as low as 14.9% to as high as 65%, likely reflecting the difference in populations studied (2,(18)(19)(20). The presence of MS is associated with the risk of developing NODAT.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients

Luan

Langewisch

2010

Clinical Transplantation

View full text Add to dashboard Cite

Background Metabolic syndrome (MS) and new onset diabetes after transplant (NODAT) are common in kidney transplant patients. We studied the relationship between the two conditions and their impact on metabolic and cardiovascular risk profiles. Methods All non-diabetic patients transplanted between 1999 and 2005 who were followed up to 2006 were included. MS and NODAT were determined. Kaplan–Meier survival and various regression analyses were performed to determine the clinical correlates for both conditions and their association with various cardiovascular risk factors. Results Among 591 patients, 314 (53.1%) had MS and 90 (15.2%) developed NODAT. The two conditions were highly associated with each other as 84 patients with NODAT also had MS (14.2%). Elevated body mass index and fasting glucose levels at transplant were risk factors for both conditions, whereas weight gain after transplant was associated only with MS. African American, old age, and hypertension-related ESRD were risk factors for NODAT. Finally, the presence of MS was associated with reduced kidney function and elevated uric acid levels, whereas the presence of NODAT with elevated pulse pressure. Conclusions MS and NODAT are highly prevalent and significantly associated with impaired metabolic and cardiovascular risk profiles. Early identification of such conditions may facilitate targeted therapeutic intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients

Luan

Langewisch

2010

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…The prevalence of MetS in this patient group was higher than expected from previous reports from kidney patients. The reported prevalence ranged between 10.7 and 30.5%, although a subgroup of renal transplant recipients with a failing graft had a MetS prevalence of 52% [2,3,4,5]. In Finland, the prevalence of MetS ranged between 30.2 and 47.8% in a population-based study using the most recent criteria for 30-79-year-old subjects and was strongly dependent on the criteria and sex [16].…”

Section: Discussionmentioning

confidence: 99%

“…In patients with chronic kidney disease (CKD), the prevalence of MetS has varied between 14 and 31% [2,3,4,5]. Some follow-up studies have suggested that MetS has an independent adverse impact on the development of CKD [6,7].…”

Section: Introductionmentioning

confidence: 99%

Metabolic Syndrome in IgA Glomerulonephritis

Kaartinen¹,

Syrjänen²,

Pörsti³

et al. 2014

Nephron Extra

View full text Add to dashboard Cite

Background/Aims: Metabolic syndrome (MetS) may have an independent impact on the development of chronic kidney disease. This study examines the prevalence of MetS in subjects with IgA glomerulonephritis (IgAGN) and its impact on disease progression in a retrospective fashion. Patients and Methods: Altogether, 174 subjects (104 males) were examined 11 years (first visit) after IgAGN diagnosis and again after 16 years (second visit; 144 subjects responded). Different glomerular filtration markers were utilized. The MetS criteria by Alberti et al. [Circulation 2009;120:1640-1645] were applied, in which the presence of any three of five risk factors (elevated waist circumference, triglycerides, glucose, existence of hypertension, or reduced high-density lipoprotein cholesterol) constitutes the diagnosis. Results: The prevalence of MetS at the first visit was 39%, corresponding to that of the general Finnish population. In univariate analyses, MetS was significantly associated with the progression of IgAGN at the second visit. However, in multivariate analyses, the existence of MetS was not a significant prognostic determinant. Conclusion: The number of subjects with MetS among IgAGN patients and the general population is equal in Finland. MetS does not seem to be an independent prognostic variable.

show abstract

“…There is also no mention about the immunosuppressive treatment and the relationship between metabolic alterations and the dosage of therapies. Among the components of the MS, systolic BP and hypertriglyceridemia had the most negative impact on long-term graft function [70][71][72][73][74][75].…”

Section: Kidney Transplantationmentioning

confidence: 99%

Prevalence of Metabolic Syndrome in Organ Transplantation: A Review of the Literature

Pinna¹,

Pagotto²

2015

Endocrinol Metab Syndr

View full text Add to dashboard Cite

The clinical features of the Metabolic Syndrome (MS) as risk factors for transplantation have been cited separately and extensively in the transplant literature. There are few studies in literature evaluating the prevalence of MS before and after solid organ transplantation.MS puts transplant patients at risk in in two ways: 1) MS is one more risk factor to be considered in the pretransplantation workup; and 2) the combined risk of cardiovascular disease post-transplantation as a side effect of immunosuppressive medication together with the risk from cardiovascular disease stemming from the MS might put a post-transplantation patient at vastly increased risk for a cardiovascular event.There are several reports on the treatment of MS expecially after transplantation; from lifestyle changes to drug therapies. However, to now, guidelines about management of these patients are lacking.

show abstract

Prevalence of the Metabolic Syndrome in Kidney Transplantation

Cited by 10 publications

References 5 publications

Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients

Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients

Metabolic Syndrome in IgA Glomerulonephritis

Prevalence of Metabolic Syndrome in Organ Transplantation: A Review of the Literature

Contact Info

Product

Resources

About